Hengrui Medicine advances oncology and kidney disease portfolio

Jiangsu Hengrui Medicine (SSE:600276) has announced significant progress in its drug development pipeline, securing approvals for clinical trials of three novel therapies and market access for one key drug. The company and its subsidiaries received the green light from the National Medical Products Administration (NMPA) for clinical trials of SHR-A1811 (injection), Adeferli monoclonal antibody injection, and Famitinib malate tablets. SHR-A1811 is being investigated in a Phase Ib/II trial in combination with antitumor drugs for solid tumors. Adeferli is being investigated as another therapeutic while Famitinib malate tablets may be used for cervical cancer.